Eisai Inc., a U.S. subsidiary of Eisai Co., a global R&D-based pharmaceutical company headquartered in Japan, plans to restructure its operations in the U.S., including a reduction of its workforce by approximately 25% across various U.S. functions. This realignment supports Eisai's desire to create a more efficient and focused organization.

"The actions we are taking will ensure Eisai stays competitive in a rapidly changing business environment," said Yuji Matsue, chairman and CEO of Eisai Inc. "Eisai remains fully committed to the U.S. market and will continue to serve the needs of patients and their families by developing and marketing important new treatments that help to satisfy unmet medical needs. Through this realignment, we will be able to redeploy our resources to support the development of our priority late-stage compounds and our current product portfolio."

The new structure is expected to be in place by May 1. Eisai Inc.'s U.S. operations include R&D, manufacturing, sales and marketing, and administrative functions. The company does not have plans to close any of its main offices or facilities.